BioPharmSignal logoBioPharmSignal

Biotech News

MoonLake Immunotherapeutics Announces Pricing of Upsized $200 Million Public Offering

MoonLake Immunotherapeutics (MLTX)MoonLake ImmunotherapeuticsFinancing

ZUG, Switzerland, June 23, 2026 – MoonLake Immunotherapeutics (NASDAQ: MLTX) (“MoonLake”), a clinical-stage biotechnology company focused on creating next-level therapies for inflammatory skin and joint diseases, today announced the pricing of an underwritten public offering of 9,000,000 Class A

Related news

HCWBHCW Biologics2026-07-29 13:06 EST

HCW Biologics Inc. Announces Pricing of $1.6 Million Private Placement Offering

HCWBHCW Biologics2026-09-24 12:25 EST

HCW Biologics Announces Pricing of $1.5 Million Private Placement

CUECue Biopharma Inc2026-07-10 01:40 EST

Cue Biopharma Announces $50.0 Million Private Placement

MLTXMoonLake Immunotherapeutics2026-08-10 11:00 EST

MoonLake Announces Positive Topline Results from the Phase 3 IZAR-1 Trial of Sonelokimab in Psoriatic Arthritis Demonstrating Significant Improvements Across all Clinical Endpoints, and Reports Second Quarter 2026 Financial Results

NRIXNurix Therapeutics2026-09-29 11:00 EST

Nurix Therapeutics Announces Achievement of $7 Million Milestone Under Strategic Collaboration with Pfizer

NRIXNurix Therapeutics2026-08-04 11:00 EST

Nurix Announces $10 Million Milestone Payment Associated with Initiation of a Phase 1 Clinical Trial of a STAT6 Degrader

INMBINmune Bio2026-07-31 11:00 EST

INmune Bio Receives R&D Rebates of Approximately $4.6 Million

View all latest news

MoonLake Immunotherapeutics

Nanobody-Based Immunology MoonLake Immunotherapeutics develops therapies for inflammatory diseases using Nanobodies, compact antibody-derived proteins designed for tissue penetration, molecular stability and multivalent target binding. Sonelokimab Sonelokimab is a trivalent Nanobody that binds IL-17A and IL-17F while also interacting...

Recent company news

MLTXMoonLake Immunotherapeutics2026-08-10 11:00 EST

MoonLake Announces Positive Topline Results from the Phase 3 IZAR-1 Trial of Sonelokimab in Psoriatic Arthritis Demonstrating Significant Improvements Across all Clinical Endpoints, and Reports Second Quarter 2026 Financial Results

MLTXMoonLake Immunotherapeutics2026-06-24 03:08 EST

MoonLake Immunotherapeutics Announces Pricing of Upsized $200 Million Public Offering

MLTXMoonLake Immunotherapeutics2026-06-22 20:01 EST

MoonLake Immunotherapeutics Announces Proposed Public Offering

MLTXMoonLake Immunotherapeutics2026-06-21 21:00 EST

MoonLake Announces Week 52 Results of Sonelokimab from its Phase 3 VELA Program in Hidradenitis Suppurativa and Confirms Investor Day on June 22, 2026

MLTXMoonLake Immunotherapeutics2026-05-10 13:00 EST

MoonLake Immunotherapeutics Announces Positive Outcome from its Final Pre-BLA Meeting with the U.S. FDA and Reports First Quarter 2026 Financial Results

Stock data

Close
11.47 USD
Market cap
1.32B USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States